AI-powered early detection of skin cancer using a smartphone

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The project will collect both retrospective and prospective anonymized photos of skin lesions plus related clinical data to validate an AI algorithm (NuvanaDx) against dermatology-confirmed diagnoses. Images will be captured by smartphones and reviewed centrally to determine the tool's sensitivity, specificity, and predictive values. The study intentionally includes diverse skin tones and populations to measure performance across groups. It will also gather user experience and workflow data to see how the app might fit into clinical triage and care pathways.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Adults (≥18 years) presenting with skin lesions suspicious for malignancy.

Ability to provide informed consent.

Exclusion Criteria:

Inability to provide informed consent.

Poor-quality images unsuitable for AI analysis.

Where it's running

• Nuvana Healthcare Ltd
  London, United Kingdom Recruiting

Study contacts

• Study coordinator: Sushma Saxena, Director, Nuvana Healthcare Ltd
• Email: sushma.saxena@nuvana.co.uk
• Phone: +44 7481986525

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Biobank for skin cancer collecting blood, tissue, and clinical data

  This project will collect blood, tissue, and clinical information from adults with melanoma or non‑melanoma skin cancer to build a biobank for future research.

  Recruiting Universitaire Ziekenhuizen KU Leuven · Leuven, Vlaams-Brabant · NCT07266142

• PD-L1-targeted PET probe to map PD-L1 in solid tumors

  A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing · NCT07848243

• ctDNA-guided stopping of immune therapy in advanced melanoma

  This study tests whether stopping immune checkpoint inhibitor therapy after 12 months is safe for patients with advanced melanoma who have undetectable ctDNA and disease control.

  Recruiting Rutgers, The State University of New Jersey · New Brunswick, New Jersey · NCT07830225

• ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients

  This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.

  Recruiting at 2 sites Tam Anh Research Institute · Hanoi, Hanoi and 1 other locations · NCT07808164

• 68Ga-SorB PET/CT imaging for solid tumors

  This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07760012

• NeoAdjuvant PD-1–Based Therapy in Resectable Advanced Melanoma (NASA)

  In people with resectable stage IIIB–IV melanoma, this study tests whether two infusions of pembrolizumab or a combination of ipilimumab plus nivolumab given before surgery can keep people alive at 2 years without needing additional adjuvant therapy.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07740941

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.